1300728-74-8

Basic information

• Product Name: lithium (S)-4-(2-(1H-imidazol-4-yl)phenyl)-2-aminobutanoate
• Synonyms: lithium (S)-4-(2-(1H-imidazol-4-yl)phenyl)-2-aminobutanoate
• CAS NO: 1300728-74-8
• Molecular Weight: 251.214
• Mol File: 1300728-74-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: lithium (S)-4-(2-(1H-imidazol-4-yl)phenyl)-2-aminobutanoate(CAS DataBase Reference)
• NIST Chemistry Reference: lithium (S)-4-(2-(1H-imidazol-4-yl)phenyl)-2-aminobutanoate(1300728-74-8)
• EPA Substance Registry System: lithium (S)-4-(2-(1H-imidazol-4-yl)phenyl)-2-aminobutanoate(1300728-74-8)

Safety Data

• Hazardous Substances Data: 1300728-74-8(Hazardous Substances Data)

Upstream product

• 1300730-84-0 (2S,5R)-2-(2-iodophenethyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine 
• 150858-45-0 2-(2-Iodophenyl)ethyl 4-toluenesulfonate 
• 1300730-85-1 (2R,5S)-2-isopropyl-3,6-dimethoxy-5-(2-(1-trityl-1H-imidazol-4-yl)phenethyl)-2,5-dihydropyrazine 

Relevant articles and documents

IMIDAZOLE DERIVATIVES AS IDO INHIBITORS

Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.